Milrinon Carinopharm (Milrinone)

Milrinone, the active ingredient in Milrinon Carinopharm, is a phosphodiesterase‑3 inhibitor presented as an intravenous solution for IV use. It is employed in the management of acute decompensated heart failure and cardiogenic shock, providing inotropic support and vasodilation in critically ill cardiac patients. The drug is administered under close hemodynamic monitoring in intensive care settings.

GNH USA supplies Milrinon Carinopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. Our distribution network reaches transplant centres and specialty clinics across multiple continents, ensuring reliable access to this critical cardiac therapy.

Milrinone is used as an inotropic and vasodilator agent in acute cardiac conditions.

Acute decompensated heart failure: improves cardiac output and reduces systemic vascular resistance. Cardiogenic shock: provides rapid inotropic support to maintain tissue perfusion. Post‑cardiac surgery low‑output syndrome: helps stabilize hemodynamics in patients with reduced ventricular function. Severe chronic heart failure awaiting transplantation: used as bridge therapy to improve hemodynamics.

Milrinone may be associated with a range of adverse reactions, varying from mild to potentially serious.

Common Side Effects: - Hypotension: may present as a sudden drop in systolic blood pressure, leading to dizziness or light‑headedness. - Headache: patients often report mild to moderate throbbing headache during infusion. - Nausea: occasional gastrointestinal upset including nausea or a feeling of queasiness. - Flushing: transient warmth and reddening of the skin, especially on the face and neck.

Serious or Rare Side Effects: - Ventricular arrhythmias: potentially life‑threatening irregular heart rhythms such as ventricular tachycardia or fibrillation. - Myocardial ischemia: reduced coronary blood flow that can cause chest pain or ECG changes. - Severe hypotension: marked blood pressure fall that may require vasopressor support. - Allergic reactions: rare cases of rash, pruritus, bronchospasm, or anaphylaxis.

Milrinone therapy requires careful monitoring and specific safety measures.

Blood pressure monitoring: check systolic and diastolic values frequently during infusion. Cardiac rhythm surveillance: continuous ECG monitoring to detect arrhythmias. Renal function adjustment: dose may need reduction in patients with severe renal impairment. Aortic stenosis caution: avoid in patients with severe aortic valve obstruction due to afterload reduction. Pregnancy and lactation: safety not established; use only if potential benefit justifies risk. Electrolyte balance: monitor potassium and magnesium levels as abnormalities increase arrhythmia risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Milrinone can interact with several drug classes; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid): - Other phosphodiesterase‑3 inhibitors: concurrent use can cause excessive vasodilation and hypotension. - Potent vasodilators (e.g., nitroglycerin, nitroprusside): may lead to severe drops in blood pressure. - Combined inotropes (e.g., dobutamine, dopamine): increase risk of ventricular arrhythmias.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt the positive inotropic effect of milrinone. - Diuretics: can cause electrolyte disturbances that predispose to arrhythmias. - ACE inhibitors or ARBs: may enhance hypotensive response. - CYP3A4 inhibitors (e.g., ketoconazole): may increase milrinone plasma concentrations.